JPY1,646.50
0.49% today
Tokyo, Sep 18, 02:15 am CET
ISIN
JP3336000009
Symbol
4536

Santen Pharmaceutical Stock price

JPY1,638.50
+56.50 3.57% 1M
+227.00 16.08% 6M
+20.00 1.24% YTD
-140.50 7.90% 1Y
+656.50 66.85% 3Y
-464.50 22.09% 5Y
-69.50 4.07% 10Y
+1,069.50 187.96% 20Y
Tokyo, Closing price Wed, Sep 17 2025
-11.50 0.70%
ISIN
JP3336000009
Symbol
4536
Industry

Key metrics

Basic
Market capitalization
JPY553.3b
Enterprise Value
JPY526.6b
Net debt
positive
Cash
JPY85.9b
Shares outstanding
336.5m
Valuation (TTM | estimate)
P/E
17.8 | 16.0
P/S
1.9 | 1.9
EV/Sales
1.8 | 1.8
EV/FCF
11.9
P/B
2.0
Dividends
DPS
JPY38.00
Yield 1Y | 5Y
2.3% | 2.5%
Growth 1Y | 5Y
5.6% | 6.3%
Payout 1Y | 3Y
34.7% | 73.5%
Increased
3 Years
Financials (TTM | estimate)
Revenue
JPY294.0b | JPY296.9b
EBITDA
JPY49.9b | JPY63.8b
EBIT
JPY41.3b | JPY55.6b
Net Income
JPY31.5b | JPY34.8b
Free Cash Flow
JPY44.3b
Growth (TTM | estimate)
Revenue
-3.4% | -1.0%
EBITDA
2.7% | 11.3%
EBIT
6.0% | 14.5%
Net Income
17.3% | -4.0%
Free Cash Flow
-39.7%
Margin (TTM | estimate)
Gross
56.3%
EBITDA
17.0% | 21.5%
EBIT
14.1%
Net
10.7% | 11.7%
Free Cash Flow
15.1%
Financial Health
Equity Ratio
69.9%
Return on Equity
12.7%
ROCE
12.8%
ROIC
11.9%
Debt/Equity
0.2
More
EPS
JPY92.9
FCF per Share
JPY131.8
Short interest
-
Employees
4k
Rev per Employee
JPY80.1m
Show more

Is Santen Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Santen Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Santen Pharmaceutical forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a Santen Pharmaceutical forecast:

Buy
77%
Hold
23%

Financial data from Santen Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
293,970 293,970
3% 3%
100%
- Direct Costs 128,591 128,591
3% 3%
44%
165,379 165,379
8% 8%
56%
- Selling and Administrative Expenses 87,792 87,792
4% 4%
30%
- Research and Development Expense 24,806 24,806
1% 1%
8%
49,853 49,853
3% 3%
17%
- Depreciation and Amortization 8,555 8,555
11% 11%
3%
EBIT (Operating Income) EBIT 41,298 41,298
6% 6%
14%
Net Profit 31,499 31,499
17% 17%
11%

In millions JPY.

Don't miss a Thing! We will send you all news about Santen Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu and currently employs 3,744 full-time employees. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.

Head office Japan
Employees 3,744
Website www.santen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today